지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
초록· 키워드
오류제보하기
Liver injury due to prescription and nonprescription medications is a growing medical, scientific, and public health problem. Worldwide, the estimated annual incidence rate of Drug-induced liver injury (DILI) is 13.9-24.0 per 100,000 inhabitants. And there is increasing concern about the potential risk for hepatotoxicity from complementary and alternative medicines (CAM) including herbal products because they are unregulated and therefore not standardized with regard to their contents. CAM, including herbal drugs and dietary supplements seem to be major causes of DILI in Asian countries, in contrast to lower incidences in Western countries. However, with increasing use of CAM, DILI from CAM seems to now be a problem all over the world. The classification and definition of the causative agents can be difficult. For example, in Korea, herbs might sub-categorize into herbal medications (medications prescribed and compounded by a doctor of oriental medicine), herbal preparations (preparations compounded by an oriental pharmacist), and medicinal herbs or plants (preparation compounded by an unauthorized lay person). Also the division of herbs and folk remedies is unclear at times. Determining hepatotoxicity remains a major challenge in clinical practice due to lack of reliable markers. Standards are lacking for validation of drug causality assessment methods. The RUCAM/CIOMS scale have been proposed to establish a causal relationship between offending drug and liver injury. Although, there is a need to validate a new instrument with an abridged scale that would provide a better approximation to the truth. It would be feasible to develop some refinements to make the RUCAM/CIOMS scale more realistic. (Korean J Med 2011;81:50-52)
목차
등록된 정보가 없습니다.
참고문헌 (5)
참고문헌 신청
/ / Drug-Induced Liver Injury: Standardization of Nomenclature and Causality Assessment. NIH Workshop, December 1-2, 2008, Bethesda, MD
/ / http://www.ncbi.nlm.nih.gov/mesh/68056486
Fontana RJ / 2009 / Rochon J for the DILIN Study Group. Drug Induced Liver Injury Network(DILIN) Prospective Study: Rationale, Design and Conduct / Drug Safety 32 : 1 ~ 14
김동준 / 2009 / 독성 간손상의 평가 / 대한소화기학회지 53 (1) : 5 ~ 14
임재희 / 2011 / 독성간염의 임상적 고찰과 조직소견 / 대한내과학회지 81 (1) : 53 ~ 63
/ / http://www.ncbi.nlm.nih.gov/mesh/68056486
Fontana RJ / 2009 / Rochon J for the DILIN Study Group. Drug Induced Liver Injury Network(DILIN) Prospective Study: Rationale, Design and Conduct / Drug Safety 32 : 1 ~ 14
김동준 / 2009 / 독성 간손상의 평가 / 대한소화기학회지 53 (1) : 5 ~ 14
임재희 / 2011 / 독성간염의 임상적 고찰과 조직소견 / 대한내과학회지 81 (1) : 53 ~ 63
이 논문의 저자 정보
최근 본 자료
댓글(0)
0